BACKGROUND AND OBJECTIVE: Central line-associated bloodstream infections (CLABSIs) frequently complicate the use of central venous catheters (CVCs) among pediatric patients with cancer. Our objectives were to describe the microbiology and identify risk factors for hospital-onset CLABSI in this patient population. DESIGN: Retrospective case-control study. SETTING: Oncology and stem cell transplant units of a freestanding, 396-bed quaternary care pediatric hospital. PARTICIPANTS: Case subjects ([Formula: see text]) were patients with a diagnosis of malignancy and/or stem cell transplant recipients with CLABSI occurring during admission. Controls ([Formula: see text]) were identified using risk set sampling of hospitalizations among patients with a CVC, matched on date of admission. METHODS: Multivariate conditional logistic regression was used to identify independent predictors of CLABSI. RESULTS: The majority of CLABSI isolates were gram-positive bacteria (58%). The most frequently isolated organism was Enterococcus faecium, and 6 of 9 isolates were resistant to vancomycin. In multivariate analyses, independent risk factors for CLABSI included platelet transfusion within the prior week (odds ratio [OR], 10.90 [95% confidence interval (CI), 3.02-39.38]; [Formula: see text]) and CVC placement within the previous month (<1 week vs ≥1 month: OR, 11.71 [95% CI, 1.98-69.20]; [Formula: see text]; ≥1 week and <1 month vs ≥1 month: OR, 7.37 [95% CI, 1.85-29.36]; [Formula: see text]). CONCLUSIONS: Adjunctive measures to prevent CLABSI among pediatric oncology patients may be most beneficial in the month following CVC insertion and in patients requiring frequent platelet transfusions. Vancomycin-resistant enterococci may be an emerging cause of CLABSI in hospitalized pediatric oncology patients and are unlikely to be treated by typical empiric antimicrobial regimens.
BACKGROUND AND OBJECTIVE: Central line-associated bloodstream infections (CLABSIs) frequently complicate the use of central venous catheters (CVCs) among pediatric patients with cancer. Our objectives were to describe the microbiology and identify risk factors for hospital-onset CLABSI in this patient population. DESIGN: Retrospective case-control study. SETTING: Oncology and stem cell transplant units of a freestanding, 396-bed quaternary care pediatric hospital. PARTICIPANTS: Case subjects ([Formula: see text]) were patients with a diagnosis of malignancy and/or stem cell transplant recipients with CLABSI occurring during admission. Controls ([Formula: see text]) were identified using risk set sampling of hospitalizations among patients with a CVC, matched on date of admission. METHODS: Multivariate conditional logistic regression was used to identify independent predictors of CLABSI. RESULTS: The majority of CLABSI isolates were gram-positive bacteria (58%). The most frequently isolated organism was Enterococcus faecium, and 6 of 9 isolates were resistant to vancomycin. In multivariate analyses, independent risk factors for CLABSI included platelet transfusion within the prior week (odds ratio [OR], 10.90 [95% confidence interval (CI), 3.02-39.38]; [Formula: see text]) and CVC placement within the previous month (<1 week vs ≥1 month: OR, 11.71 [95% CI, 1.98-69.20]; [Formula: see text]; ≥1 week and <1 month vs ≥1 month: OR, 7.37 [95% CI, 1.85-29.36]; [Formula: see text]). CONCLUSIONS: Adjunctive measures to prevent CLABSI among pediatric oncology patients may be most beneficial in the month following CVC insertion and in patients requiring frequent platelet transfusions. Vancomycin-resistant enterococci may be an emerging cause of CLABSI in hospitalized pediatric oncology patients and are unlikely to be treated by typical empiric antimicrobial regimens.
Authors: Adil A H Abbas; Christopher J H Fryer; Charles Paltiel; Fares Chedid; Sami K Felimban; Abdulmotalib A Yousef; Taha M Khattab Journal: Pediatr Blood Cancer Date: 2004-04 Impact factor: 3.167
Authors: J Casado-Flores; A Valdivielso-Serna; L Pérez-Jurado; J Pozo-Román; M Monleón-Luque; J García-Pérez; A Ruiz-Beltran; M A García-Teresa Journal: Intensive Care Med Date: 1991 Impact factor: 17.440
Authors: Sean M Berenholtz; Peter J Pronovost; Pamela A Lipsett; Deborah Hobson; Karen Earsing; Jason E Farley; Shelley Milanovich; Elizabeth Garrett-Mayer; Bradford D Winters; Haya R Rubin; Todd Dorman; Trish M Perl Journal: Crit Care Med Date: 2004-10 Impact factor: 7.598
Authors: Michael L Rinke; Allen R Chen; David G Bundy; Elizabeth Colantuoni; Lisa Fratino; Kim M Drucis; Stephanie Y Panton; Michelle Kokoszka; Alicia P Budd; Aaron M Milstone; Marlene R Miller Journal: Pediatrics Date: 2012-09-03 Impact factor: 7.124
Authors: M Tavadze; L Rybicki; S Mossad; R Avery; M Yurch; B Pohlman; H Duong; R Dean; B Hill; S Andresen; R Hanna; N Majhail; E Copelan; B Bolwell; M Kalaycio; R Sobecks Journal: Bone Marrow Transplant Date: 2014-08-11 Impact factor: 5.483
Authors: Matthew S Kelly; Margaret Conway; Kathleen E Wirth; Gail Potter-Bynoe; Amy L Billett; Thomas J Sandora Journal: J Pediatr Hematol Oncol Date: 2013-03 Impact factor: 1.289
Authors: Michael L Rinke; Aaron M Milstone; Allen R Chen; Kara Mirski; David G Bundy; Elizabeth Colantuoni; Miriana Pehar; Cynthia Herpst; Marlene R Miller Journal: Pediatr Blood Cancer Date: 2013-07-23 Impact factor: 3.167
Authors: R A Ammann; H J Laws; D Schrey; K Ehlert; O Moser; D Dilloo; U Bode; A Wawer; A Schrauder; G Cario; A Laengler; N Graf; R Furtwängler; A Simon Journal: Eur J Pediatr Date: 2015-03-26 Impact factor: 3.183
Authors: Sung W Choi; Lawrence Chang; David A Hanauer; Jacqueline Shaffer-Hartman; Daniel Teitelbaum; Ian Lewis; Alex Blackwood; Nur Akcasu; Janell Steel; Joy Christensen; Matthew F Niedner Journal: Pediatr Blood Cancer Date: 2012-04-22 Impact factor: 3.167